Anebulo Pharmaceuticals (FRA:214) Total Assets : €5.52 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals Total Assets?

Anebulo Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 was €5.52 Mil.

During the past 12 months, Anebulo Pharmaceuticals's average Total Assets Growth Rate was 216.80% per year. During the past 3 years, the average Total Assets Growth Rate was 420.50% per year.

During the past 4 years, Anebulo Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 420.50%. The lowest was 420.50%. And the median was 420.50%.

Total Assets is connected with ROA %. Anebulo Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 was -98.24%. Total Assets is also linked to Revenue through Asset Turnover. Anebulo Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 was 0.00.

Anebulo Pharmaceuticals Total Assets Historical Data

The historical data trend for Anebulo Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals Total Assets Chart

Anebulo Pharmaceuticals Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Total Assets

2.69

17.97

14.74

10.77

Anebulo Pharmaceuticals Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial										13.48	10.77	8.48	6.88	5.52

Anebulo Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Anebulo Pharmaceuticals's Total Assets for the fiscal year that ended in Jun. 2023 is calculated as

Total Assets	=	Total Equity (A: Jun. 2023 )	+	Total Liabilities (A: Jun. 2023 )
	=	9.785	+	0.987
	=	10.77

Anebulo Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	4.586	+	0.929
	=	5.52

Anebulo Pharmaceuticals (FRA:214) Total Assets Explanation

Total Assets is connected with ROA %.

Anebulo Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-6.088	/	( (6.878	+	5.516)	/ 2 )
	=	-6.088	/	6.197
	=	-98.24 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Anebulo Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	0	/	( (6.878	+	5.516)	/ 2 )
=	0	/	6.197
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Anebulo Pharmaceuticals Total Assets Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Anebulo Pharmaceuticals (FRA:214) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ANEB:USA

Address

1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734

Website

https://www.anebulo.com

Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Anebulo Pharmaceuticals (FRA:214) Headlines

No Headlines